Discovery of a tribenzophenazine analog for binding to the KRAS mRNA G-quadruplex structures in the cisplatin-resistant non–small cell lung cancer
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.108164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Xiao-Dong Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Nation-Regional Engineering Lab for Synthetic Biology of Medicine, International Cancer Center, School of Pharmacy, Shenzhen University Medical Schoo…. Hauptthemen laut MEDLINE: G-Quadruplexes, Proto-Oncogene Proteins p21(ras), Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Shenzhen Science and Technology Innovation Program.
Abstract (Originalsprache)
Lung cancer is the malignant tumor with the highest morbidity and mortality rate worldwide, of which non-small cell lung cancer (NSCLC) accounts for approximately 85%. KRAS mutations are one of the significant mechanisms underlying the occurrence, development, immune escape, and chemotherapy resistance of NSCLC. Two KRAS inhibitors are approved by Food and Drug Administration for the treatment of NSCLC in the past 3 years. However, they are only effective to KRAS G12C mutant, and moreover, innate and acquired drug resistance is already reported, leaving an urgent need to block KRAS pathways through novel targets. In this study, we focused on the discovery of ligands targeting the RNA G-quadruplexes in 5'-UTR of KRAS mRNA, and a novel tribenzophenazine analog (MBD) was identified as the lead compound. Further mechanisms were discussed in A549/DDP cells, a cisplatin-resistant and KRAS-mutant NSCLC cell line. Antitumor efficacy was verified both in vitro in A549/DDP cells, and in vivo in a nude mouse xenograft model implanted with A549/DDP cells. To sum up, our results suggest the potential of MBD as a prominent anti-KRAS-driven NSCLC agent and propose a new idea for the development of small molecule ligands targeting KRAS RNA G-quadruplexes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nation-Regional Engineering Lab for Synthetic Biology of Medicine, International Cancer Center, School of Pharmacy, Shenzhen University Medical School, Shenzhen, China.
- Nation-Regional Engineering Lab for Synthetic Biology of Medicine, International Cancer Center, School of Pharmacy, Shenzhen University Medical School, Shenzhen, China. Electronic address: humhao1229@szu.edu.cn.
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- Shenzhen Science and Technology Innovation Program
Zitieren
APA
Wang, X. D., Lin, J. H., & Hu, M. H. (2025). Discovery of a tribenzophenazine analog for binding to the KRAS mRNA G-quadruplex structures in the cisplatin-resistant non–small cell lung cancer. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.108164
Vancouver
Wang XD, Lin JH, Hu MH. Discovery of a tribenzophenazine analog for binding to the KRAS mRNA G-quadruplex structures in the cisplatin-resistant non–small cell lung cancer. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.108164
BibTeX
@article{Wang2025,
author = {Wang, Xiao-Dong and Lin, Jia-Hong and Hu, Ming-Hao},
title = {Discovery of a tribenzophenazine analog for binding to the KRAS mRNA G-quadruplex structures in the cisplatin-resistant non–small cell lung cancer},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.108164}
}
EUVIMED